Core Insights - IN8bio is prioritizing its clinical program for INB-100 in acute myeloid leukemia (AML), reporting a 100% progression-free survival rate as of August 30, 2024 [1][8] - The company is suspending enrollment in the Phase 2 clinical trial of INB-400 for newly diagnosed glioblastoma (GBM) while continuing to monitor existing patients [2][4] - A workforce reduction of approximately 49% is being implemented to optimize resource allocation and preserve cash resources [2][10] Clinical Programs - INB-100 for AML is the primary focus, with plans to enroll approximately 25 additional patients in the expansion cohort, targeting completion in the first half of 2025 [6] - The company aims to affirm the positive clinical data for INB-100, which has shown a 100% relapse-free survival rate after a median follow-up of 18.7 months [8][7] - INB-200 has completed patient treatment, while enrollment in INB-400 is on hold as the company seeks partnership opportunities [4][9] Financial and Operational Strategy - The workforce reduction is expected to be completed in the third quarter of 2024, with one-time costs of approximately $0.3 million primarily related to severance [10] - The company is focusing on key milestones to generate near-term interest and value creation, particularly through the INB-100 program [5] - IN8bio had a Type B meeting with the FDA, receiving guidance on advancing INB-100 as a post-transplant maintenance therapy [7]
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia